



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Walke and Scoville

Application No.: 10/008,574

Filed: October 26, 2001

Title: Novel Human 7TM Proteins and Polynucleotides
Encoding the Same

Attorney Docket No.: LEX-0264-USA

Group Art Unit: 1645

Examiner: To Be Assigned

#17

Assistant Commissioner for Patents
Box DD
Arlington, VA 22202

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

X under 37 CFR 1.97(b), or

(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

___ under 37 CFR 1.97(c) together with either a:

___ Certification under 37 CFR 1.97(e), or

___ a \$240.00 fee under 37 CFR 1.17(p), or

(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

___ under 37 CFR 1.97(d) together with a:

___ Certification under 37 CFR 1.97(e), and

___ a petition under 37 CFR 1.97(d)(2)(ii), and

___ a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

I, the applicant, patent(s), publications or other information on which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that under 37 CFR § 1.97 (e)(1) each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application not more than three (3) months prior to the filing of this Information Disclosure Statement.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

March 19, 2003
Date

Lance K. Ishimoto by [Signature] Reg. No. 41,866
Lance K. Ishimoto Reg. No. 41,866

LEXICON GENETICS INCORPORATED
8800 Technology Forest Place
The Woodlands, TX 77381
(281) 863-3333



24231

PATENT TRADEMARK OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/008,574
				Filing Date	Oct 26, 2001
				First Named Inventor	Walke
				Group Art Unit	1645
				Examiner Name	Not Yet Assigned
Shee	1	of	1	Attorney Docket Number	LEX-0264-USA
(use as many sheets as necessary)					

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office	Number ⁴	Kind Code ⁵ (if known)				
	DX		WO 02 22665 A		Takeda Chemical Industries	03-21-2002		
	DY		WO 02 26825 A		Incyte Genomics	04-04-2002		
	DZ		WO 02 29050 A		Bayer Aktiengesellschaft	04-11-2002		
	EA		WO 02 29051 A		Bayer Aktiengesellschaft	04-11-2002		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EB	DATABASE EMBL 19 May 2000, CORBY N.: "Human DNA sequence from clone RP11-550C4 on chromosome 6", Database accession no. AL356421, XP002229817, Postions 56940-58380	
	EC	DATABASE EMBL 22 March 2000, SIMS S.: "Human DNA sequence from clone RP11-337K13 *Sequencing cancelled*", Database accession no. AL161776, XP002229818, Positions 119530-120990	
	ED	ICHTCHENKO K ET AL: "A NOVEL UBIQUITOUSLY EXPRESSED ALPHA-LATROTOXIN RECEPTOR IS A MEMBER OF THE CIRL FAMILY OF G-PROTEIN-COUPLED RECEPTORS" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 9, 26 February 1999, pages 5491-5498, XP000828192, ISSN: 0021-9258	
	EE	LELIANOVA V G ET AL: "ALPHA-LATROTOXIN RECEPTOR, LATROPHILIN, IS A NOVEL MEMBER OF THE SECRETIN FAMILY OF G PROTEIN-COUPLED RECEPTORS" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 34, 22 August 1997, pages 21504-21508, XP002066460, issn: 0021-9258	
	EF	OSTERHOFF C ET AL: "CLONING OF A HUMAN EPIDIDYMIS-SPECIFIC MRNA, HE6, ENCODING A NOVEL MEMBER OF THE SEVEN TRANSMEMBRANE-DOMAIN RECEPTOR SUPERFAMILY" DNA AND CELL BIOLOGY, NEW YORK, NY, US, vol. 16, no. 4, 1997, pages 379-389, XP002925525, ISSN:1044-5498	
	EG	STADEL J M ET AL: "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 18, no. 11, 1 November 1997, pages 430-437, XP004099345, ISSN 0165-6147.	
	EH	SUGITA S ET AL: "ALPHA-LATROTOXIN RECEPTOR CIRL/LATROPHILIN 1 (CL1) DEFINES AN UNUSUAL FAMILY OF UBIQUITOUS G-PROTEIN-LINKED RECEPTORS" JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC., US, vol. 273, no. 49, 1998, pages 32715-32724, XP000946649, issn: 0021-9258	
	EI	International Search Report	

--	--

This form is a continuation of the information provided in the application for a patent. It is not to be used for the purpose of filing a separate application. The information provided in this form is for the use of the Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE, and is not to be used for any other purpose. The information provided in this form is for the use of the Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE, and is not to be used for any other purpose.

Buyer's Statement: This form is submitted to the Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE, and is not to be used for any other purpose. The information provided in this form is for the use of the Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE, and is not to be used for any other purpose.

Please type a plus sign (+) inside this box → ☐

PTO/SB.21 (08-00)

Approval for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

10/008,574

Filing Date

Oct 26, 2001

First Named Inventor

Walke, D. Wade

Group Art Unit

1645

Examiner Name

Not Yet Assigned

Total Number of Pages in This Submission

5 pgs +
12 references

Attorney Docket Number

LEX-0264-USA

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment / Reply

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Supplemental Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

☐ Assignment Papers (for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) _____

Remarks

☐ After Allowance Communication to Group

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please identify below):

- Return Postcard
- Supplemental Form PTO1449 and Copies of (12) References Cited
- International Search Report as Ref EI

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm

Lexicon Genetics Incorporated

or

Individual name

Lance K. Ishimoto

Reg. No. 41,866

Signature

Lance K. Ishimoto by David W. Hager



24231

PATENT TRADEMARK OFFICE

Date

March 19, 2003

CERTIFICATE OF MAILING

Typed or printed name

Michelle Klein

Signature

Michelle Klein

Date

March 19, 2003